)
Claritev (CTEV) investor relations material
Claritev Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Business model and affordability
Out-of-network cost containment addresses 7%-8% of U.S. healthcare spend; the independent PPO network contracts with 1.4 million providers.
Payment and revenue integrity processes over 5.5 billion claims annually, including pre-payment claim review, payment accuracy, coordination of benefits and subrogation.
New transparency-based pricing solution processes over 500 billion machine-readable-file records monthly; data supports out-of-network pricing and cost containment.
Healthcare inflation indicators point to double-digit increases next year; employer health insurance premiums may rise 10%, increasing focus on affordability and transparency.
Growth and go-to-market
LTM revenue surpassed $1 billion and EBITDA exceeded $600 million at Q3 end; YTD bookings reached $100 million, with 78% from existing clients.
More than 50% of YTD bookings came from outside the core payer segment; expansion includes providers, government, international markets, brokers and employers.
Go-to-market and delivery investment is expected at $20 million-$25 million this year; management expects continued investment in sales, marketing and go-to-market functions.
The $325 million sales funnel spans new logos, existing clients and multiple sectors; next year's bookings could be in the same order of magnitude as this year's.
Segment performance
Claims intelligence was a Q3 growth bright spot, supported by a No Surprises Act client win booked in Q1 and converted to revenue earlier than modeled.
Network revenue, excluding $18.6 million of prior-year one-time property and casualty revenue, was up mid-single digits; the World Trade Center network deal carries $5 million ACV.
Over the last four quarters, PRI booked ~$40 million of new business, with only a fraction converted to revenue; management expects a return to growth next year.
Final No Surprises Act rulings are viewed as a net tailwind; IDR disputes are expected to reach 3.5 million this year versus an original estimate of 15,000-20,000 annually.
- Revenue growth and bookings supported raised FY26 guidance and a FY27 outlook of at least $1.1B.CTEV
Q3 2026 - AI-driven transformation and new market expansion propel robust growth and operational agility.CTEV
Morgan Stanley 24th Annual Global Healthcare Conference - Transformation drives growth, margin strength, and leadership in healthcare claims innovation.CTEV
Canaccord Genuity's 46th Annual Growth Conference - Q2 2026 revenue up 6.6%, guidance raised, but legal and IT risks remain.CTEV
Q2 2026 - Record bookings, tech investment, and strong client ties drive ambitious 2030 growth targets.CTEV
Bank of America Global Healthcare Conference 2026 - Transformation and innovation drive growth, profitability, and expanded market reach.CTEV
44th Annual J.P. Morgan Healthcare Conference - Six new market segments, tech innovation, and a $200M pipeline drive growth into 2026.CTEV
BofA Securities Leveraged Finance Conference 2025 - Q1 2025 revenue was $231.3M, net loss narrowed, and transformation advanced.CTEV
Q1 2025 - 2024 net loss surged on a $1.49B impairment as transformation and rebranding drive long-term optimism.CTEV
Q4 2024
)
)
)
)
)
)
)
)